Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension
NCT00350844 · Ann & Robert H Lurie Children's Hospital of Chicago · PHASE1/PHASE2 · terminated · last registry update 2026-09-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low subject accrual” | – | Registry record, Ann & Robert H Lurie Children's Hospital of Chicago |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RRM1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Also stopped (suspended): National Cancer Institute (NCI), azacytidine + carboplatin (NCT06694454)
- 2026-11-09Phase 3 first posted: CSPC Megalith Biopharmaceutical Co.,Ltd., SYS6010 combined with Enlonstobart + Tislelizumab combined with chemotherapy (NCT07925021)
- 2026-11-09Results posted on the registry: Memorial Sloan Kettering Cancer Center, LY2880070 + Gemcitabine (NCT05275426)
- 2026-11-04Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nab-paclitaxel + Gemcitabine (NCT04753879)
- 2026-11-04Also stopped (suspended): Masonic Cancer Center, University of Minnesota, E7777 + Fludarabine (NCT04855253)
- 2026-11-04Also stopped (suspended): Institute of Hematology & Blood Diseases Hospital, China, RD13-02 (NCT06622694)
- 2026-11-04Also stopped (terminated): InnoPharmax Inc., D07001-softgel capsules + Xeloda (or TS-1) + mFOLFOX (NCT05065957)
- 2026-11-04Results posted on the registry: Jazz Pharmaceuticals, ZW25 (Zanidatamab) + Capecitabine (NCT03929666)
- 2026-11-03Results posted on the registry: Columbia University, Gemcitabine + Cisplatin (NCT06571708)
- 2026-11-03Also stopped (terminated): Columbia University, Gemcitabine + Cisplatin (NCT06571708)
- 2026-11-03Phase 3 first posted: Assiut University, Sequential Systemic Chemotherapy (NCT07914101)
- 2026-11-03Also stopped (suspended): National Cancer Institute (NCI), Emavusertib + Gemcitabine Hydrochloride (NCT05685602)
- 2026-10-30Also stopped (terminated): Shenzhen Geno-Immune Medical Institute, Antigen-specific IgT cells (NCT03170141)
- 2026-10-29Phase 3 first posted: Kite, A Gilead Company, Anitocabtagene Autoleucel + Isatuximab (NCT07903506)
- 2026-10-29Also stopped (terminated): Arsenal Biosciences, Inc., AB-1015 (NCT05617755)
- 2026-10-29Also stopped (terminated): Hebei Yanda Ludaopei Hospital, CD19/CD20 Dual-CAR-T cells (NCT04260932)
- 2026-10-28Phase 3 first posted: Shanghai Hengrui Pharmaceutical Co., Ltd., HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection + HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection (NCT07900789)
- 2026-10-27Also stopped (terminated): Adicet Therapeutics, ADI-270 + Fludarabine (NCT06480565)
- 2026-10-27Results posted on the registry: Brandon Huffman, MD, Zentalis + Gemzar (NCT06015659)
- 2026-10-27Also stopped (terminated): Brandon Huffman, MD, Zentalis + Gemzar (NCT06015659)
- 2026-10-27Results posted on the registry: Washington University School of Medicine, Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan (NCT01821781)
- 2026-10-21Phase 3 first posted: Kite, A Gilead Company, Anitocabtagene autoleucel + Daratumumab (NCT07887672)
- 2026-10-19Also stopped (withdrawn): Emory University, Prophylactic Transfusion Intervention group: Transfusion (NCT06979492)
- 2026-10-19Also stopped (terminated): Boston Children's Hospital, cyclosporine + horse anti-thymocyte globulin (ATG) (NCT05600426)
- 2026-10-16Also stopped (suspended): National Cancer Institute (NCI), Cyclophosphamide + Fludarabine (NCT07055477)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision